# Coagulopathy and Vasculopathy Assessment as a Predictor of the Severity of SARS-CoV-2 / COVID-19 Infection

> **NCT04624997** · — · UNKNOWN · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 1000 (estimated)

## Conditions studied

- COVID-19
- SARS-CoV-2 Infection

## Interventions

- **OTHER:** biological sample

## Key facts

- **NCT ID:** NCT04624997
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-08
- **Primary completion:** 2022-12
- **Final completion:** 2022-12
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2022-01-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04624997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04624997, "Coagulopathy and Vasculopathy Assessment as a Predictor of the Severity of SARS-CoV-2 / COVID-19 Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04624997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*